{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:56:41Z","timestamp":1788883001506,"version":"build-2803163510"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The United States and China are among the largest hubs for oncology drug development and commercialization. We conducted a comprehensive characterization of how the 2 largest oncology drug markets are evolving relative to one another, with implications for regulators, sponsors, clinicians, and patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using publicly available drug databases from the US Food and Drug Administration (FDA) and the National Medical Products Administration (NMPA), we collected information on novel oncology approvals in the United States and China from 2020 to 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 2020 to 2025, the FDA approved 87 oncology drugs, whereas the NMPA approved 94; most (87% FDA and 65% NMPA) were approved through expedited mechanisms. From 2023 to 2025, the NMPA's approval volume increased and exceeded that of the FDA. Overall, the FDA reviewed drugs a median of 182 days faster, approved them a median of 164 days earlier, and had more global first-in-class approvals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>As regulatory capacity expands globally, cross-national comparisons help identify approaches that are working well and inform continued innovation and regulatory modernization in the United States to ensure timely patient access to innovative oncology therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/haschl\/qxag183","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:53:10Z","timestamp":1783597990000},"source":"Crossref","is-referenced-by-count":1,"title":["A cross-national review of novel oncology approvals in the United States and China (2020-2025)"],"prefix":"10.1093","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4114-5938","authenticated-orcid":false,"given":"Grace","family":"Collins","sequence":"first","affiliation":[{"name":"Friends of Cancer Research , Washington, DC 20036 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2018-4252","authenticated-orcid":false,"given":"Divita","family":"Pandita","sequence":"additional","affiliation":[{"name":"Friends of Cancer Research , Washington, DC 20036 ,","place":["United States"]},{"name":"Carey School of Law, University of Pennsylvania , Philadelphia, PA 19104 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0177-2024","authenticated-orcid":false,"given":"Hillary","family":"Andrews","sequence":"additional","affiliation":[{"name":"Friends of Cancer Research , Washington, DC 20036 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3001-4951","authenticated-orcid":false,"given":"Bernat","family":"Navarro-Serer","sequence":"additional","affiliation":[{"name":"Friends of Cancer Research , Washington, DC 20036 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4728-1976","authenticated-orcid":false,"given":"Elena","family":"Levi-D\u2019Ancona","sequence":"additional","affiliation":[{"name":"Friends of Cancer Research , Washington, DC 20036 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0586-3054","authenticated-orcid":false,"given":"Jeff","family":"Allen","sequence":"additional","affiliation":[{"name":"Friends of Cancer Research , Washington, DC 20036 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4847-0736","authenticated-orcid":false,"given":"Mark","family":"Stewart","sequence":"additional","affiliation":[{"name":"Friends of Cancer Research , Washington, DC 20036 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"issue":"3","key":"2026072014404218600_qxag183-B1","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s43441-022-00480-3","article-title":"Regulatory pathways supporting expedited drug development and approval in ICH member countries","volume":"57","author":"Franco","year":"2023","journal-title":"Ther Innov Regul Sci"},{"key":"2026072014404218600_qxag183-B2","author":"Office of the Commissioner"},{"key":"2026072014404218600_qxag183-B3","author":"Office of the Commissioner."},{"key":"2026072014404218600_qxag183-B4","author":"Office of the Commissioner"},{"key":"2026072014404218600_qxag183-B5","author":"Office of the Commissioner"},{"key":"2026072014404218600_qxag183-B6","author":"National Medical Products Administration"},{"key":"2026072014404218600_qxag183-B7","author":"National Medical Products Administration"},{"key":"2026072014404218600_qxag183-B8","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.2147\/DDDT.S514132","article-title":"New drug approvals in China: an international comparative analysis, 2019-2023","volume":"19","author":"Yan","year":"2025","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"2026072014404218600_qxag183-B9","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/cpt.70084","article-title":"Innovative drugs approved in China after registration classification reform: current status, disparities, and challenges","volume":"119","author":"Zhu","year":"2026","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"2026072014404218600_qxag183-B10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41571-023-00728-3","article-title":"Newly approved cancer drugs in China\u2014innovation and clinical benefit","volume":"20","author":"Zhang","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"2026072014404218600_qxag183-B11","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/d41573-021-00080-0","article-title":"Characteristics of expedited programmes for cancer drug approval in China","volume":"20","author":"Li","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"2026072014404218600_qxag183-B12","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/d41573-025-00153-4","article-title":"Breakthrough therapy designations in China and the United States","volume":"24","author":"Mao","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"2026072014404218600_qxag183-B13","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1056\/NEJMp2505821","article-title":"The rise of drug innovation in China\u2014implications for patient access in the United States and globally","volume":"393","author":"Vokinger","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"2026072014404218600_qxag183-B14","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/s41392-025-02267-y","article-title":"Current landscape of innovative drug development and regulatory support in China","volume":"10","author":"Tan","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"15","key":"2026072014404218600_qxag183-B15","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1001\/jama.2026.2390","article-title":"The geography of pharmaceutical innovation: the US and China in a new world order","volume":"335","author":"Pazdur","year":"2026","journal-title":"JAMA"},{"issue":"15","key":"2026072014404218600_qxag183-B16","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1001\/jama.2026.1962","article-title":"Geographic shifts in early-stage biopharmaceutical innovation","volume":"335","author":"Kang","year":"2026","journal-title":"JAMA"},{"key":"2026072014404218600_qxag183-B17","author":"Center for Drug Evaluation and Research"},{"key":"2026072014404218600_qxag183-B18","author":"Center for Biologics Evaluation and Research"},{"key":"2026072014404218600_qxag183-B19","author":"Center for Drug Evaluation and Research"},{"key":"2026072014404218600_qxag183-B20","author":"Center for Drug Evaluation, National Medical Products Administration"},{"key":"2026072014404218600_qxag183-B21","author":"Center for Drug Evaluation, National Medical Products Administration"},{"key":"2026072014404218600_qxag183-B22","author":"Center for Drug Evaluation, National Medical Products Administration"},{"key":"2026072014404218600_qxag183-B23","author":"Center for Drug Evaluation, National Medical Products Administration"},{"key":"2026072014404218600_qxag183-B24","author":"Center for Drug Evaluation, National Medical Products Administration"},{"key":"2026072014404218600_qxag183-B25","author":"Center for Drug Evaluation, National Medical Products Administration"},{"key":"2026072014404218600_qxag183-B26","author":"Center for Drug Evaluation, National Medical Products Administration"},{"key":"2026072014404218600_qxag183-B27","author":"Center for Drug Evaluation, National Medical Products Administration"},{"key":"2026072014404218600_qxag183-B28","author":"Center for Drug Evaluation, National Medical Products Administration"},{"issue":"3","key":"2026072014404218600_qxag183-B29","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/d41573-026-00028-2","article-title":"Approvals by the China NMPA in 2025","volume":"25","author":"Jing","year":"2026","journal-title":"Nat Rev Drug Discov"},{"key":"2026072014404218600_qxag183-B30","author":"U.S. Food and Drug Administration"},{"key":"2026072014404218600_qxag183-B31","author":"Oncology Center of Excellence"},{"key":"2026072014404218600_qxag183-B32","author":"Friends of Cancer Research"}],"container-title":["Health Affairs Scholar"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/advance-article-pdf\/doi\/10.1093\/haschl\/qxag183\/68742777\/qxag183.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/4\/7\/qxag183\/68742777\/qxag183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/4\/7\/qxag183\/68742777\/qxag183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T18:40:49Z","timestamp":1784572849000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article\/doi\/10.1093\/haschl\/qxag183\/8729649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,3]]}},"URL":"https:\/\/doi.org\/10.1093\/haschl\/qxag183","relation":{},"ISSN":["2976-5390"],"issn-type":[{"value":"2976-5390","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7]]},"article-number":"qxag183"}}